17. Biktarvy

Biktarvy is sweeping up patients from Gilead's older HIV meds. (Gilead Sciences)

Company: Gilead Sciences
2019 sales: $4.74 billion
Projected 2026 sales: $11.4 billion
Projected CAGR: +14%
Used for: HIV

Taking the crown as a drugmaker's best launch ever is no easy feat, but that's exactly what three-drug HIV regiment Biktarvy did for Gilead Sciences in its first full year on the market in 2019. Driven by superior efficacy over older, two-drug therapies, Biktarvy could keep pushing into megablockbuster territory in the coming years.

Biktarvy hit $4.74 billion in sales in 2019 and could post impressive 14% annual growth through 2026, Evaluate Pharma forecast. That increase would put Biktarvy at $11.4 billion in sales by that year, among the biggest hauls in pharma. 

Within Gilead's extensive HIV portfolio, Biktarvy stands out for its three-drug formulation and also its skyrocketing sales, which have bucked a troubling trend for the drugmaker. 

RELATED: Gilead touts new data for fast-growing Biktarvy as older HIV meds show some cracks

17. Biktarvy